title: Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.
abstract: OBJECTIVE
  To investigate the expression of annexin a1 (ANXA1) in adriamycin-resistant human bladder cancer cell line (pumc-91/ADM) compared with the parental cell line (pumc-91) and its relevance to the drug resistance of bladder cancer, as well as explore the relevance of ANXA1 in recurrent bladder cancer tissues as pertinent to relapse.
  
  
  METHODS
  qRT-PCR and Western blot were implemented to research the level of ANXA1 in two cell lines (pumc-91/ADM and pumc-91). Immunohistochemistry was applied to explore ANXA1 expression in bladder cancer tissues of different intervals of relapse. The association of ANXA1 with clinicopathological parameters was analyzed.
  
  
  RESULTS
  The expression of ANXA1 was downregulated in drug-resistant cell line pumc-91/ADM compared to pumc-91. The bladder cancer tissues recurring two years later exhibited higher ANXA1 levels. ANXA1 expression level was positively correlated with T stage, while it was not connected with histological grade strongly. The expression level and influencing factors of ANXA1 in recurrent tissues of bladder cancer were clarified for the first time.
  
  
  CONCLUSIONS
  ANXA1 may become a promising marker to predict the recurrence and drug resistance of bladder cancer and provide guidance for surveillance.
authors.affiliation: Department of Clinical Laboratory Center, Beijing Shijitan Hospital, Capital Medical University Beijing, China.
authors.forename: Shuliang
authors.initials: S
authors.lastname: Yu
authors.affiliation: Department of Clinical Laboratory Center, Beijing Shijitan Hospital, Capital Medical University Beijing, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Meng
authors.affiliation: Department of Clinical Laboratory Center, Beijing Shijitan Hospital, Capital Medical University Beijing, China.
authors.forename: Huihui
authors.initials: H
authors.lastname: Hu
authors.affiliation: Department of Clinical Laboratory Center, Beijing Shijitan Hospital, Capital Medical University Beijing, China.
authors.forename: Man
authors.initials: M
authors.lastname: Zhang
mesh_terms: D017305:Annexin A1 / Q000235:genetics / Q000378:metabolism*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation; D004317:Doxorubicin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: D017305:Annexin A1; D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D004317:Doxorubicin
keywords: Bladder cancer; annexin a1 (ANXA1); drug resistance; recurrence